P/E ratio for Pacira Biosciences (PCRX)
P/E ratio as of April 2024 (TTM): 188
According to Pacira Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 188.071. At the end of 2022 the company had a P/E ratio of 110.
P/E ratio history for Pacira Biosciences from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 110 | 74.17% |
| 2021 | 63.3 | 257.75% |
| 2020 | 17.7 | -110.55% |
| 2019 | -168 | -92.2% |
| 2018 | < -1000 | 5036.01% |
| 2017 | -41.9 | 30.96% |
| 2016 | -32.0 | -101.67% |
| 2015 | > 1000 | -961.4% |
| 2014 | -222 | 644.1% |
| 2013 | -29.8 | 194.98% |
| 2012 | -10.1 | 225.71% |
| 2011 | -3.10 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Zogenix ZGNX | -6.56 | -103.49% | 🇺🇸 USA |
 Recro Pharma
REPH | -2.79 | -101.48% | 🇺🇸 USA |
 Omeros Corporation OMER | 4.91 | -97.39% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Heron Therapeutics HRTX | -2.11 | -101.12% | 🇺🇸 USA |
 Cara Therapeutics
CARA | -0.3302 | -100.18% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.